A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

NCT02413008 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Vaginal Atrophy

Interventions

DRUG: estriol
DRUG: Placebo

Sponsor

ITF Research Pharma, S.L.U.

Collaborators

[object Object]